Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostSubmitted by Chris Markoch. Posted: 2/5/2026. 
Quick Look - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer reported adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 drug candidate. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> PFE stock closed up 4% on Feb. 4 as analysts and investors had an opportunity to digest the report. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. In fact, data shows that the global GLP-1 market will grow from $62.2 billion in 2025 to $157 billion by 2035. This implies a compound annual growth rate (CAGR) of 9.7% and explains why billions of dollars are flowing into the industry from companies looking to carve out market share. For Pfizer, that opportunity centers on its lead GLP-1 candidate, MET-097i. The company announced results from its Phase 2b VESPER-3 study. The trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also highlighted that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of the 28 weeks. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom pointed to the positive clinical trial results as the primary reason for the stock's gain. That may be true, but investors should recognize this could be a short-term sugar high. While Pfizer's GLP-1 program shows promise, it will take time for that to materially affect the company's financials. Plus, the GLP-1 trade is expanding quickly, and major competitors remain entrenched — as the earnings report from Eli Lilly & Co. (NYSE: LLY) demonstrates. However, there are other reasons to be bullish on PFE. One is its growing oncology portfolio. Data from Business Research Insights values the global oncology drugs market at approximately $264.92 billion in 2026. That's projected to climb to $648.08 billion by 2035, reflecting a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had roughly 60 candidates in its product portfolio — each representing another chance to capture market share. The company's pipeline was strengthened significantly by its acquisition of Seagen in 2023. Today, Pfizer's pipeline includes both late-stage candidates and earlier programs. Examples include Vepdegestrant (a next-generation targeted protein degrader, or PROTAC) and atirmociclib (a selective CDK4 inhibitor), which are being evaluated in later-stage trials for ER+/HER2- metastatic breast cancer. Other notable late-stage programs include: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (for example, Be6A LUNG-01) against metastatic non-small cell lung cancer, leveraging ADC expertise gained from the Seagen acquisition.
- Sasanlimab, which targets bladder cancer, and a bispecific PD-1xVEGF agent (PF-4404), which is being studied in combination with Padcev to treat urothelial cancer — positioning these programs as potential blockbusters amid oncology growth.
And as noted earlier, Pfizer could be bringing multiple drugs to market over the next five to 10 years. That outlook is enhanced by the company's commitment to artificial intelligence (AI), which is becoming essential across the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships with firms such as Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics, reportedly speeding target identification by at least 50% with tools like OncoScout. Internally, platforms like "Charlie" handle data mining, predictions, and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) help optimize discovery and manufacturing. These efforts were important in the company's rapid development of Paxlovid and support expected 2026 catalysts in oncology and obesity. Pfizer is targeting $1.2 billion in savings by 2027 through efficiency gains tied to AI and digital tools. Industrywide, AI is projected to boost productivity by 35% to 45% by improving preclinical decision-making and trial design, making it a core competitive edge rather than optional hype. Pfizer's front-loaded adoption of these technologies should be a tailwind for investors over the medium and long term. In short, while GLP-1 headlines may drive short-term excitement, Pfizer's deeper upside may come from a diversified oncology pipeline and accelerating AI-driven efficiencies — a combination that could deliver more durable growth over time.
| 
